Actinium Pharmaceuticals (ATNM) Revenue (2021 - 2026)

Actinium Pharmaceuticals (ATNM) posted quarterly Revenue of $90000.0 for Q3 2025, up 100.0% quarter-over-quarter from $45000.0 in Q3 2022.

Actinium Pharmaceuticals (ATNM) Revenue (2021 - 2026) Analysis & Trends

Actinium Pharmaceuticals (ATNM) has reported Revenue for 3 consecutive years, with $90000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Revenue changed N/A year-over-year to $90000.0; the TTM figure through Dec 2025 stood at $135000.0 (changed N/A YoY), while the FY2025 annual figure was $90000.0, changed N/A from the prior year.
Revenue rose to $90000.0 in Q3 2025 per ATNM's latest filing, from $45000.0 in the prior quarter.
Across five years, Revenue topped out at $940000.0 in Q1 2022 and bottomed at $23000.0 in Q4 2021.
Historically, Revenue has averaged $283000.0 across 3 years, with a median of $161500.0 in 2021.
On a YoY basis, Revenue climbed as much as 51.13% in 2022 and fell as far as 83.08% in 2022.
Actinium Pharmaceuticals' Revenue stood at $23000.0 in 2021, then soared by 95.65% to $45000.0 in 2022, then surged by 100.0% to $90000.0 in 2025.
Business Quant data shows ATNM's Revenue at $90000.0 in Q3 2025, $45000.0 in Q3 2022, and $45000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	674.14 Mn
10	Actinium Pharmaceuticals	35.01 Mn	35.01 Mn	-	35.00 Mn

Download Data